Literature DB >> 11816893

Autoimmune inner ear disease: steroid and cytotoxic drug therapy.

J M Lasak1, R T Sataloff, M Hawkshaw, T E Carey, K M Lyons, J R Spiegel.   

Abstract

The goal of this study was to assess the effects of immunosuppressive therapy on hearing in patients with presumed autoimmune sensorineural hearing loss (AISNHL) and a Western blot assay positive for a 68 kD inner ear antigen. To achieve this objective, we conducted a retrospective review of 39 such patients who were treated with either a steroid alone or with a steroid followed by a cytotoxic agent. Pure-tone average (PTA) at 500 Hz, 1 kHz, 2 kHz, and 3 kHz, and speech discrimination scores (SDS) were used as objective measures of outcome. At the completion of treatment, 23 of the 39 patients (59.0%) exhibited a positive response to therapy. The steroid-only responders (n = 6) tended to demonstrate a greater improvement in PTA (14.8 vs 4.5 dB), while the cytotoxic-agent responders (n = 17) had a significantly greater improvement in SDS (26.2 vs 6.9%; p < 0.01). We conclude that most patients with AISNHL benefit from immunosuppressive therapy and that cytotoxic medications appear to improve SDS, even in some patients who have not responded to corticosteroid therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11816893

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  6 in total

Review 1.  Immunosuppressive therapy for autoimmune inner ear disease.

Authors:  Maria C Buniel; Katie Geelan-Hansen; Peter C Weber; Vincent K Tuohy
Journal:  Immunotherapy       Date:  2009-05       Impact factor: 4.196

Review 2.  Demystifying autoimmune inner ear disease.

Authors:  Soumyajit Das; Satvinder Singh Bakshi; Ramesh Seepana
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-10-11       Impact factor: 2.503

3.  Artemisinin Loaded mPEG-PCL Nanoparticle Based Photosensitive Gelatin Methacrylate Hydrogels for the Treatment of Gentamicin Induced Hearing Loss.

Authors:  Xiaohua Li; Yanchun Wang; Feilong Xu; Feng Zhang; Ying Xu; Lei Tang; Thomas J Webster
Journal:  Int J Nanomedicine       Date:  2020-06-25

Review 4.  Emerging options in immune-mediated hearing loss.

Authors:  Hitomi Sakano; Jeffrey P Harris
Journal:  Laryngoscope Investig Otolaryngol       Date:  2018-12-03

Review 5.  Autoimmune inner ear disease: A systematic review of management.

Authors:  Nathaniel K Breslin; Varun V Varadarajan; Eric S Sobel; Rex S Haberman
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-11-28

Review 6.  Immune system of the inner ear as a novel therapeutic target for sensorineural hearing loss.

Authors:  Takayuki Okano
Journal:  Front Pharmacol       Date:  2014-09-02       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.